Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Definity

(Perflutren)

Small molecule

LLantheus Medical Imaging

0

Indications

2

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

11

Patents

Clinical

Trials by Indication[1]

Liver Metastases1 trial

Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

Completed·SStanford University·N/A·NCT01631318·34 enrolled

Renal Blood Flow1 trial

Monitoring Renal Blood Flow With Contrast Enhanced Ultrasound During Coronary Angiogram

Unknown status·UUniversity of Virginia·N/A·NCT01544036·150 enrolled

Regulatory

FDA Approval Timeline[3]

Jul 31, 2001

DEFINITY

NDA NDA021064

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Perflutren. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Perflutren compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA021064). U.S. Food & Drug Administration.
[4]
FDA Orange Book — Patent and exclusivity data for Definity. U.S. Food & Drug Administration.
[5]
SEC EDGAR — Lantheus Medical Imaging company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: LLantheus Medical Imaging

Patent Landscape[4]

Patent Cliff

Dec 28, 2035

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10022460Dec 28, 2035

10583207Dec 28, 2035

11395856Dec 28, 2035

9789210Mar 16, 2037

11857646Mar 16, 2037

6 more patents

11266750Mar 16, 2037

12161730Mar 16, 2037

11529431Mar 16, 2037

10583208Mar 16, 2037

11925695Mar 16, 2037

10588988May 4, 2037

Related News